123 related articles for article (PubMed ID: 34292111)
1. Selective obstruction of the mTORC2 complex by a naturally occurring cholestane saponin (OSW-1) for inhibiting prostate cancer cell growth.
Elgehama A
J Asian Nat Prod Res; 2022 Jul; 24(7):663-672. PubMed ID: 34292111
[No Abstract] [Full Text] [Related]
2. Cholestane glycosides from Ornithogalum saundersiae bulbs and the induction of apoptosis in HL-60 cells by OSW-1 through a mitochondrial-independent signaling pathway.
Iguchi T; Kuroda M; Naito R; Watanabe T; Matsuo Y; Yokosuka A; Mimaki Y
J Nat Med; 2019 Jan; 73(1):131-145. PubMed ID: 30327993
[TBL] [Abstract][Full Text] [Related]
3. Effective cytotoxic activity of OSW-1 on colon cancer by inducing apoptosis in vitro and in vivo.
Zhang Y; Fang F; Fan K; Zhang Y; Zhang J; Guo H; Yu P; Ma J
Oncol Rep; 2017 Jun; 37(6):3509-3519. PubMed ID: 28440433
[TBL] [Abstract][Full Text] [Related]
4. Sterol-recognition ability and membrane-disrupting activity of Ornithogalum saponin OSW-1 and usual 3-O-glycosyl saponins.
Malabed R; Hanashima S; Murata M; Sakurai K
Biochim Biophys Acta Biomembr; 2017 Dec; 1859(12):2516-2525. PubMed ID: 28947142
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of cholestane glycosides bearing OSW-1 disaccharide or its 1-->4-linked analogue and their antitumor activities.
Zheng D; Zhou L; Guan Y; Chen X; Zhou W; Chen X; Lei P
Bioorg Med Chem Lett; 2010 Sep; 20(18):5439-42. PubMed ID: 20719510
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of cholestane saponins as mimics of OSW-1 and their cytotoxic activities.
Zheng D; Guan Y; Chen X; Xu Y; Chen X; Lei P
Bioorg Med Chem Lett; 2011 Jun; 21(11):3257-60. PubMed ID: 21530251
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of analogues of a potent antitumor saponin OSW-1.
Morzycki JW; Wojtkielewicz A; Wołczyński S
Bioorg Med Chem Lett; 2004 Jun; 14(12):3323-6. PubMed ID: 15149699
[TBL] [Abstract][Full Text] [Related]
8. Effect of OSW-1 on microRNA expression profiles of hepatoma cells and functions of novel microRNAs.
Jin JC; Jin XL; Zhang X; Piao YS; Liu SP
Mol Med Rep; 2013 Jun; 7(6):1831-7. PubMed ID: 23588479
[TBL] [Abstract][Full Text] [Related]
9. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
10. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
11. OSW-1 inhibits tumor growth and metastasis by NFATc2 on triple-negative breast cancer.
Ding X; Li Y; Li J; Yin Y
Cancer Med; 2020 Aug; 9(15):5558-5569. PubMed ID: 32515123
[TBL] [Abstract][Full Text] [Related]
12. Dynamic modeling of signal transduction by mTOR complexes in cancer.
Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
[TBL] [Abstract][Full Text] [Related]
13. Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.
Facompre ND; Sinha I; El-Bayoumy K; Pinto JT; Sinha R
Int J Cancer; 2012 Nov; 131(9):2134-42. PubMed ID: 22307455
[TBL] [Abstract][Full Text] [Related]
14. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
15. Anticancer saponin OSW-1 is a novel class of selective Golgi stress inducer.
Kimura M; Sasaki K; Fukutani Y; Yoshida H; Ohsawa I; Yohda M; Sakurai K
Bioorg Med Chem Lett; 2019 Jul; 29(14):1732-1736. PubMed ID: 31126855
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
[TBL] [Abstract][Full Text] [Related]
17. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
18. OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.
Zhou Y; Garcia-Prieto C; Carney DA; Xu RH; Pelicano H; Kang Y; Yu W; Lou C; Kondo S; Liu J; Harris DM; Estrov Z; Keating MJ; Jin Z; Huang P
J Natl Cancer Inst; 2005 Dec; 97(23):1781-5. PubMed ID: 16333034
[TBL] [Abstract][Full Text] [Related]
19. Interactions of OSW-1 with Lipid Bilayers in Comparison with Digitonin and Soyasaponin.
Malabed R; Hanashima S; Murata M; Sakurai K
Langmuir; 2020 Apr; 36(13):3600-3610. PubMed ID: 32160747
[TBL] [Abstract][Full Text] [Related]
20. The 3.2-Å resolution structure of human mTORC2.
Scaiola A; Mangia F; Imseng S; Boehringer D; Berneiser K; Shimobayashi M; Stuttfeld E; Hall MN; Ban N; Maier T
Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33158864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
